| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Greg Zante is Chief Financial Officer at VKTX. Greg Zante's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.5M at current prices.
Our model assigns Greg Zante a middling insider score of 55/100, based on 14 past trades. Over a 12-month horizon, 41.7% of those trades were profitable, with an average 12-month return of -35.5%.
The VKTX filings lean toward selling, a net 636,496 shares.
Greg Zante has 19 Form 4 filings on record from January 2021 to July 2026, all as Chief Financial Officer at Viking Therapeutics (VKTX), 2021–2026.
The 88 reported transactions were 30 open-market sales, 20 stock awards, 18 option exercises and 14 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $26.1M.
The largest open-market sale was 131,687 shares of VKTX at an average $76.61 on October 28, 2024, about $10.1M. Twelve months later VKTX was down 53%.
2 of the 12 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 10 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 21,217 | $33.47 | $710,141.48 | -9.1% | -25.5% | - | |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 57,661 | $32.90 | $1,896,969.39 | -23.3% | +5.6% | - | |
| Oct 28, 2025 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 6,185 | $35.00 | $216,480.57 | -3.4% | -9.2% | -27.4% | |
| Jul 3, 2025 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 4,266 | $27.76 | $118,428.43 | -2.5% | -2.9% | +32.8% | |
| Jan 6, 2025 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 50,309 | $42.75 | $2,150,594.66 | -23.3% | -50.0% | -24.1% | |
| Oct 28, 2024 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 131,687 | $76.61 | $10,089,164.06 | -46.9% | -55.1% | -53.1% | |
| Jul 30, 2024 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 16,136 | $57.15 | $922,212.06 | -7.9% | +31.8% | -40.4% | |
| May 3, 2024 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 66,756 | $74.69 | $4,986,007.97 | -27.6% | -29.0% | -61.9% | |
| Jan 4, 2024 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sell | 15,000 | $17.90 | $268,500.00 | -7.7% | +322.2% | +130.8% | |
| Apr 17, 2023 | VKTX Viking Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 7,500 | $20.00 | $150,000.00 | -4.8% | -21.1% | +246.2% |